The use of roflumilast in COPD: A primary care perspective

Primary Care Respiratory Journal

Volumn 19, Issue 4, 2010, Pages 342-351

  Price, David ^a   Chisholm, Alison ^b   Ryan, Dermot ^c   Crockett, Alan ^d   Jones, Rupert ^e  

^a Research in Real Life   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Woodbrook Medical Centre   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Chronic bronchitis; COPD; Exacerbations; Maintenance treatment; PDE4 inhibitors; Phenotypes; Primary care; RCT evidence; Roflumilast; Severe

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; BRONCHODILATING ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG USE; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; GENERAL PRACTITIONER; HEART ARRHYTHMIA; HUMAN; LUNG EMPHYSEMA; MAINTENANCE THERAPY; NAUSEA; NONHUMAN; PATIENT SELECTION; PHYSICIAN ATTITUDE; PNEUMONIA; PRIMARY MEDICAL CARE; REVIEW; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADULT; AMINOPYRIDINES; BENZAMIDES; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOPROPANES; DRUG THERAPY, COMBINATION; HUMANS; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 79551617104     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2010.00066     Document Type: Review

References (30)

1. World Health Organization. World Health Statistics 2008. Available online at http://www.who.int/whosis/whostat/2008/en/index.html [Last accessed: 6/11/09].
2. Healthcare Commission. Clearing the air: A national study of chronic obstructive pulmonary disease. Healthcare Commission, 2006
3. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and Asthma in Primary Care Patients 40 Years of Age and Over. J Asthma 2006;43(1):75-80. http://dx.doi.org/10.1080/02770900500448738
4. Price D, Freeman D, Cleland J, Kaplan A, Cerasoli F. Earlier diagnosis of COPD in primary care and earlier treatment. Prim Care Resp J 2010. http://dx.doi.org/10.4104/pcrj.2010.00060
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2009 update. www.goldcopd.com. Last accessed 1-12-2009
6. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. Clinical guideline 12. Thorax 2004;59(Suppl I):i1-i232.
7. Levy ML, Fletcher M, Price DB, Hausen T, Halbert RJ, Yawn BP. International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care. Prim Care Resp J 2006;15:20-34. http://dx.doi.org/ 10.1016/j.pcrj.2005.10.004
8. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007;14 Suppl B:5B-32B.
9. Celli BR, MacNee W, and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46. http://dx.doi.org/10.1183/09031936.04.00014304
10. Tashkin D, Rennard S, Taylor Hays J, et al. Efficacy and safety of varenicline for smoking cessation in patients with mild to moderate COPD. Chest Meeting Abstracts. 2009;136:151S-b-152S-b.
11. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3:CD001287.
12. Fletcher CM, Elmes PC, Fairbairn MB, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959;2:257-66.
13. Singh D, Brooks J, Hagan G, et al. Superiority of triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63(7):592-8. http://dx.doi.org/10.1136/thx.2007.087213
14. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374(4691):685-94. http://dx.doi.org/10.1016/S0140-6736(09)61255-1
15. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-tosevere chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Lancet 2009; 374(4691):695-703. http://dx.doi.org/10.1016/S0140-6736(09)61252-6
16. European Medicines Agency Science Medicines Health. Summary of opinion (initial authorisation) Daxas: roflumilast. 22 April 2010. Available online at: http://www.ema.europa.eu/pdfs/human/opinion/Daxas_15986110en.pdf
17. MacIntyre NR. Chronic obstructive pulmonary disease: emerging medical therapies. Respir Care 2004;49(1):6-9.
18. Pettersen CA, Adler KB. Airways Inflammation and COPD. Chest 2002;121(5 Suppl):142S-150S. http://dx.doi.org/10.1378/chest.121.5_suppl.142S
19. Molet S, Belleguic C, Lena H, et al. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflammation Res. 2005;54(1):31-6. http://dx.doi.org/10.1007/s00011-004-1319-4
20. Barnes PJ. Mechanisms in COPD: Differences from asthma. Chest 2000;117(2 Suppl):10S-14S. http://dx.doi.org/10.1378/chest.117.2_suppl.10S
21. Barnes PJ. COPD: is there light at the end of the tunnel? Curr Opin Pharmacol 2004;4(3):263-72. http://dx.doi.org/10.1016/j.coph.2004.03.001
22. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004;364(9438):985-96. http://dx.doi.org/10.1016/S0140- 6736(04)17025-6
23. Dastidar SG, Ray A, Shirumalla R, et al. Pharmacology of a novel, orally active PDE4 inhibitor. Pharmacology 2009;83(5):275-86. http://dx.doi.org/10.1159/000209608
24. Martinez FJ, Calverley PMA, Goehring UM, et al. Defining patient populations in COPD: Experience with roflumilast. COPD7 2010; Abstract 12. Available at: http://www.copdconferences.org
25. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16. http://dx.doi.org/10.1111/j.1398-9995.2004.00772.x
26. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008;63(9):761-7. http://dx.doi.org/10.1136/thx.2007.089193
27. Optimum Patient Care. Audit Review Services. May 2010. Available online at: http://www.optimumpatientcare.org/audit/audit.html
28. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009;180:1189-95. http://dx.doi.org/10.1164/rccm.200902-0271OC
29. Poolson JB, Kazanowski JJ, Goldman AL, Szentivanyi A. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol 1978;5:535-39. http://dx.doi.org/10.1111/j.1440-1681.1978.tb00707.x
30. Lahu G, Huennemeyer A, von Richter O, et al. Effect of Single and Repeated Doses of Ketoconazole on the Pharmacokinetics of Roflumilast and Roflumilast N-Oxide. J Clin Pharmacol 2008;11:1339-49. http://dx.doi.org/10.1177/0091270008321941